Deutsche Bank initiated coverage of Compass Pathways with a Buy rating and $16 price target. Compass is focused on lead asset is COMP360, a novel formulation of psilocybin, in development for treatment-resistant depression, or TRD, and based on results of a Phase 2b study for COMP360 in TRD the firm thinks the odds of success in the ongoing Phase 3s is “very high,” or 75%-plus, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CMPS:
- Here’s What You Missed in Cannabis, Psychedelics This Week
- Compass Pathways appoints Teri Loxam as Chief Financial Officer
- Compass Pathways appoints Loxam as CFO
- Compass Pathways: Psilocybin treatment results in bipolar II published in JAMA
- Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry